Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Novartis
MSD R&D (China) Co., Ltd.
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Massachusetts General Hospital
Galapagos NV
ImmunityBio, Inc.
ADC Therapeutics S.A.
Janssen Research & Development, LLC
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Pennsylvania
Eli Lilly and Company
Lyell Immunopharma, Inc.
Eli Lilly and Company
Autolus Limited
Medical University of South Carolina
TORL Biotherapeutics, LLC
Lyell Immunopharma, Inc.
AstraZeneca
M.D. Anderson Cancer Center
City of Hope Medical Center
Instituto de Investigación Biomédica de Salamanca
BeOne Medicines
The Lymphoma Academic Research Organisation
National Institutes of Health Clinical Center (CC)
Northwestern University
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Indiana University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Gustave Roussy, Cancer Campus, Grand Paris
National Research Center for Hematology, Russia
Baylor College of Medicine
Eli Lilly and Company
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
AstraZeneca
Excyte Biopharma Ltd
Celgene
Gilead Sciences
Regeneron Pharmaceuticals